Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which chemo works best before esophageal cancer surgery? new study aims to find out

NCT ID NCT02359968

First seen Mar 24, 2026 · Last updated May 25, 2026 · Updated 11 times

Summary

This study looked at 106 people with esophageal or junction cancer that could be removed by surgery. Before surgery, patients received either a standard three-drug chemo (FOLFOX) or a two-drug combo (paclitaxel plus carboplatin) along with radiation. The goal was to see which approach leads to more complete tumor removal and fewer serious complications after surgery. The results help doctors choose the best treatment plan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRO-ESOPHAGEAL JUNCTION CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CH Lyon sud

    Pierre-Bénite, France

  • CHU Bordeaux

    Bordeaux, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital La Timone

    Marseille, France

  • Hôpital Nord

    Marseille, France

  • ICM - Val d'Aurelle

    Montpellier, France

  • ICO Paul Papin

    Angers, France

  • ICO René Gauducheau

    Saint-Herblain, France

  • University Hospital of Lille

    Lille, 59000, France

Conditions

Explore the condition pages connected to this study.